Citation Tools
BSG 2016
PTH-084 Cost-Effectiveness of Vedolizumab Compared with Infliximab, Adalimumab, and Golimumab for Treatment of Moderately-to-Severely Active Ulcerative Colitis in The United Kingdom
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- PTH-084 Cost-Effectiveness of Vedolizumab Compared with Infliximab, Adalimumab, and Golimumab for Treatment of Moderately-to-Severely Active Ulcerative Colitis in The United Kingdom